HDAC9 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population engineered for functional interrogation of HDAC9, a class IIa histone deacetylase. This product provides a genomically disrupted HDAC9 pool in the HAP1 background, enabling loss-of-function studies without the biases of clonal selection. The polyclonal format reflects the diversity of editing events across the population, offering a robust model for phenotype-driven screens and signaling analyses.
The host HAP1 cell line is a near-haploid human chronic myeloid leukemia (CML) derivative of KBM-7, retaining single copies of most chromosomes except for disomy of chromosome 8. It constitutively expresses the BCR-ABL1 fusion oncogene, providing a malignancy-relevant context. The near-haploid karyotype simplifies gene targeting and enhances signal-to-noise in functional genomics screens, making it exceptionally suited for drug sensitivity profiling and oncogenic pathway dissection.
HDAC9 functions as a signal-responsive transcriptional corepressor that catalyzes deacetylation of lysine residues on histone H3 and H4, as well as non-histone substrates including p53, Ku70, and estrogen receptor alpha. Its activity is dynamically regulated by phosphorylation via calcium/calmodulin-dependent protein kinase (CaMK) and protein kinase D (PKD), which promote 14-3-3 protein binding and subsequent nuclear export, thereby relieving repression of target genes. HDAC9 directly interacts with transcription factors such as MEF2 and NFAT and assembles into multiprotein complexes containing N-CoR/SMRT corepressors and HDAC3. Through these interactions, it integrates signals from T cell receptor, calcium, p38 MAPK, Wnt, and TGF-beta pathways to control gene expression programs governing cardiac growth, immune cell differentiation, and genome stability.
Within the HAP1 near-haploid environment, HDAC9 knockout clarifies its regulatory roles by eliminating functional redundancy and amplifying phenotypic readouts. This model enables precise analysis of histone acetylation changes, derepression of MEF2 target genes, and modulation of apoptosis. The BCR-ABL1-driven leukemic background further allows investigation of HDAC9??s impact on cancer cell survival, DNA repair via Ku70 deacetylation, and sensitivity to HDAC inhibitors, providing a pertinent system for epigenetic drug target validation.
Applications include functional genomics screening to identify HDAC9-dependent vulnerabilities, signal transduction studies, and drug sensitivity profiling. Validated assays encompass western blotting for HDAC9 and downstream effectors, RT-qPCR for transcriptional readouts, ChIP-qPCR for histone modification status, co-immunoprecipitation of MEF2-HDAC9 complexes, and flow cytometry for cell cycle and apoptosis. The polyclonal knockout pool is also suitable for immunofluorescence localization studies and phospho-signaling pathway analysis. For technical information or custom applications, please contact Ascent Research.
